Recent Achievements about Targeted Alpha Therapy-Based Targeting Vectors and Chelating Agents
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
One of the most rapidly growing options in the management of cancer therapy is Targeted Alpha Therapy (TAT) through which lethal α-emitting radionuclides conjugated to tumor-targeting vectors selectively deliver high amount of radiation to cancer cells.225Ac, 212Bi, 211At, 213Bi, and 223Ra have been investigated by plenty of clinical trials and preclinical researches for the treatment of smaller tumor burdens, micro-metastatic disease, and post-surgery residual disease. In order to send maximum radiation to tumor cells while minimizing toxicity in normal cells, a high affinity of targeting vectors to cancer tissue is essential. Besides that, the stable and specific complex between chelating agent and α-emitters was found as a crucial parameter. The present review was planned to highlight recent achievements about TAT-based targeting vectors and chelating agents and provide further insight for future researches.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Anti-cancer agents in medicinal chemistry - 22(2022), 8 vom: 30., Seite 1496-1510 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Farzipour, Soghra [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
8BR2SOL3L1 |
|---|
| Anmerkungen: |
Date Completed 17.05.2022 Date Revised 31.05.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2174/1871520621666210727120308 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM328600989 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM328600989 | ||
| 003 | DE-627 | ||
| 005 | 20231225203301.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1871520621666210727120308 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1095.xml |
| 035 | |a (DE-627)NLM328600989 | ||
| 035 | |a (NLM)34315393 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Farzipour, Soghra |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Recent Achievements about Targeted Alpha Therapy-Based Targeting Vectors and Chelating Agents |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.05.2022 | ||
| 500 | |a Date Revised 31.05.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a One of the most rapidly growing options in the management of cancer therapy is Targeted Alpha Therapy (TAT) through which lethal α-emitting radionuclides conjugated to tumor-targeting vectors selectively deliver high amount of radiation to cancer cells.225Ac, 212Bi, 211At, 213Bi, and 223Ra have been investigated by plenty of clinical trials and preclinical researches for the treatment of smaller tumor burdens, micro-metastatic disease, and post-surgery residual disease. In order to send maximum radiation to tumor cells while minimizing toxicity in normal cells, a high affinity of targeting vectors to cancer tissue is essential. Besides that, the stable and specific complex between chelating agent and α-emitters was found as a crucial parameter. The present review was planned to highlight recent achievements about TAT-based targeting vectors and chelating agents and provide further insight for future researches | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Targeted alpha therapy | |
| 650 | 4 | |a actinium | |
| 650 | 4 | |a bifunctional chelators | |
| 650 | 4 | |a carrier molecule | |
| 650 | 4 | |a radioimmunotherapy | |
| 650 | 4 | |a radionuclide | |
| 650 | 7 | |a Chelating Agents |2 NLM | |
| 650 | 7 | |a Radium-223 |2 NLM | |
| 650 | 7 | |a 8BR2SOL3L1 |2 NLM | |
| 650 | 7 | |a Actinium |2 NLM | |
| 650 | 7 | |a NIK1K0956U |2 NLM | |
| 650 | 7 | |a Radium |2 NLM | |
| 650 | 7 | |a W90AYD6R3Q |2 NLM | |
| 700 | 1 | |a Shaghaghi, Zahra |e verfasserin |4 aut | |
| 700 | 1 | |a Abbasi, Sahar |e verfasserin |4 aut | |
| 700 | 1 | |a Albooyeh, Hajar |e verfasserin |4 aut | |
| 700 | 1 | |a Alvandi, Maryam |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Anti-cancer agents in medicinal chemistry |d 2006 |g 22(2022), 8 vom: 30., Seite 1496-1510 |w (DE-627)NLM160693403 |x 1875-5992 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2022 |g number:8 |g day:30 |g pages:1496-1510 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/1871520621666210727120308 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2022 |e 8 |b 30 |h 1496-1510 | ||